The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Med.
Sec. Nuclear Medicine
Volume 12 - 2025 |
doi: 10.3389/fmed.2025.1477275
This article is part of the Research Topic Advances in the Management of Lung Cancer: From the Bench to the Bedside and Back View all 11 articles
Baseline 18 F-FDG PET/CT Parameters in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer
Provisionally accepted
Lu Zheng 1
yanzhu Bian 1* yujing Hu 2*
Congna Tian 2 xinchao Zhang 2* shuheng Li 3* xin Yang 4* yanan Qin 4*- 1 Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Department of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, Hebei Province, China
- 2 Hebei General Hospital, Shijiazhuang, China
- 3 Department of Nuclear Medicine, Affiliated Hospital of Hebei University, Baoding, Hebei Province, China
- 4 Department of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, Hebei Province, China
Objective: To analyse positron emission tomography/ computed tomography (PET/CT) imaging and clinical data from patients with non-small cell lung cancer (NSCLC), to identify characteristics of survival beneficiaries of immune checkpoint inhibitors (ICIs) treatment and to establish a survival prediction model.: A retrospective analysis was conducted on PET/CT imaging and clinical parameters of 155 NSCLC patients who underwent baseline PET/CT examination at the Department of Nuclear Medicine, Hebei General Hospital. The Kaplan-Meier curve was employed to compare progression-free survival (PFS) and overall survival (OS) between the ICIs and non-ICIs group and to assess the impact of variables on PFS and OS in the ICIs group. Multivariate Cox proportional hazards regression analysis was conducted with parameters significantly associated with survival in univariate analysis. Results: Significant differences were observed in PFS (χ 2 = 11.910, P = 0.0006) and OS (χ 2 = 8.343, P = 0.0039). Independent predictors of PFS in the ICIs group included smoking history[hazard ratio (HR) = 2.522, 95% confidence interval (CI): 1.044 ~ 6.091, P = 0.0398], SUVmax of the primary lesion(HR = 0.2376, 95%CI: 0.1018 ~ 0.5548, P = 0.0009), MTVp(HR = 0.0755, 95%CI: 0.0284 ~ 0.2003, P < 0.001), and TLGp(HR = 0.1820, 95%CI: 0.0754 ~ 0.4395, P = 0.0002). These were also independent predictors of OS in the ICIs group[HR(95%CI) were 2.729 (1.125 ~ 6.619), 0.2636 (0.1143 ~ 0.6079), 0.0715 (0.0268 ~ 0.1907), 0.2102 (0.0885 ~ 0.4992), both P < 0.05)]. Age was an additional independent predictor of OS(HR = 0.4140, 95%CI: 0.1748 ~ 0.9801, P = 0.0449). Conclusions: Smoking history, primary lesion SUVmax, MTVp, and TLGp were independent predictors of PFS, while age, smoking history, SUVmax, MTVp, and TLGp were independent predictors of OS in the ICIs group. Patients without a history of smoking and with SUVmax ≤ 19.2, MTVp ≤ 20.745cm 3 , TLGp ≤ 158.62g, and age ≤ 60 years benefited more from ICI treatment.
Keywords: PET/CT, SUV, Non-small cell lung cancer, immune checkpoint inhibitors, prognosis
Received: 07 Aug 2024; Accepted: 20 Jan 2025.
Copyright: © 2025 Zheng, Bian, Hu, Tian, Zhang, Li, Yang and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
yanzhu Bian, Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Department of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, 050051, Hebei Province, China
yujing Hu, Hebei General Hospital, Shijiazhuang, China
xinchao Zhang, Hebei General Hospital, Shijiazhuang, China
shuheng Li, Department of Nuclear Medicine, Affiliated Hospital of Hebei University, Baoding, Hebei Province, China
xin Yang, Department of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, 050051, Hebei Province, China
yanan Qin, Department of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, 050051, Hebei Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.